InnovAge Announces Release of CMS Sanction in Sacramento Center

Published on November 22, 2022

DENVER, Nov. 22, 2022 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (the “Company” or “InnovAge”) (Nasdaq: INNV), a market leading healthcare delivery platform for high-cost, dual-eligible seniors, announced today that the Centers for Medicare & Medicaid Services (CMS) has determined that effective

Continue reading on website
Other news

Antibody Engineering and Therapeutics

November 22, 2022
Abzena will be attending Antibody Engineering & Therapeutics Event from 4th-8th December 2022! See us at booth 403! We will be hosting a talk with speaker Daniel Giroux, Ph.D.Title of Talk: From Sequence to toxicology batch in Half the Time by Use of Stable Pools and Platform MethodsDate and time of talk:Scientific Briefing 1 – Pacific BallroomDec 7: 12-12.30pm The post Antibody Engineering and Th

Leveraging Stable Pool Material to Expedite the Path to IND Webinar

November 24, 2022
Regulatory filing and approval is the first major value inflection point of drug development. With rising numbers of antibody-based therapeutics entering the development pipeline, and increased competition, there is growing pressure for biopharma developers to reduce timelines to regulatory submissions. Critical to reducing these timelines is having an integrated approach to development, coordinat